Loading…
C4 Therapeutics, Inc. is projected to rise to $5.82 by 2027, a +43% move from its current price of $4.06. CCCC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $3.90 | $4.06 | $4.23 | +0.11% |
| Jul 14 | $3.84 | $4.07 | $4.31 | +0.23% |
| Jul 15 | $3.80 | $4.07 | $4.37 | +0.34% |
| Jul 16 | $3.76 | $4.08 | $4.42 | +0.46% |
| Jul 17 | $3.73 | $4.08 | $4.47 | +0.57% |
| Jul 18 | $3.70 | $4.09 | $4.51 | +0.69% |
| Jul 19 | $3.68 | $4.09 | $4.55 | +0.80% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.68 | $4.09 | $4.55 | +0.80% |
| Week 2 | $3.55 | $4.13 | $4.80 | +1.61% |
| Week 3 | $3.46 | $4.16 | $5.00 | +2.43% |
| Week 4 | $3.39 | $4.19 | $5.19 | +3.25% |
| Week 5 | $3.33 | $4.23 | $5.37 | +4.08% |
| Week 6 | $3.28 | $4.26 | $5.53 | +4.92% |
| Week 7 | $3.24 | $4.29 | $5.70 | +5.76% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
It is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co.
Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
C4 Therapeutics, Inc. (CCCC) is a healthcare company trading with a current price of $4.34 and a market capitalization of $479.86M. It is ranked 3101 by market cap. These figures place the stock in the mid-cap space with a clinically focused biotechnology profile.
A major floor 42.1% below — a decisive break under it would weaken the trend.
The nearest floor, 11.8% below — buyers have tended to step in here.
The nearest ceiling, 15.0% above — a clean break opens room to run.
A major ceiling 27.9% above — clearing it would confirm fresh momentum.
Key CCCC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CCCC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.21 | Sell | $4.20 | Sell |
| MA 10 | $4.30 | Sell | $4.23 | Sell |
| MA 20 | $4.17 | Sell | $4.15 | Sell |
| MA 50 | $3.75 | Buy | $3.81 | Buy |
| MA 100 | $3.24 | Buy | $3.39 | Buy |
| MA 200 | $2.75 | Buy | $3.05 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.66 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -43.21 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -3.79 | Sell |
| Bollinger %B (20,2) | 0.37 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.68 | Buy |
| Awesome (5,34) | 0.16 | Buy |
| Ultimate (7,14,28) | 34.67 | Neutral |
| Momentum (10) | -0.34 | Sell |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 4.17 | Sell |
| ADX (14) | 16.64 | Neutral |
| ATR (14) | 0.16 | Info |
The near-term price trajectory is framed by a bullish technical backdrop, with RSI14 at 60. The stock’s technicals show a 50-day simple moving average of $3.60 and a 200-day simple moving average of $2.72. Support is at $3.11 and resistance at $4.67, outlining a trading band that reflects a potential for upside momentum.
The 30-day range spans from a low of $3.26 to a high of $5.78, indicating volatility within a relatively wide trading window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.71 | $4.06 | $6.13 | 0% | Neutral | |
| $4.42 | $5.82 | $8.20 | +43% | Bullish | |
| $5.41 | $7.43 | $11.03 | +83% | Bullish | |
| $6.01 | $8.55 | $13.21 | +111% | Bullish | |
| $5.92 | $8.71 | $13.90 | +115% | Bullish | |
| $5.85 | $8.88 | $14.58 | +119% | Bullish | |
| $5.92 | $9.24 | $15.56 | +128% | Bullish | |
| $7.54 | $12.09 | $20.83 | +198% | Bullish | |
| $9.20 | $15.13 | $26.62 | +273% | Bullish | |
| $9.02 | $15.22 | $27.30 | +275% | Bullish | |
| $12.40 | $23.53 | $45.72 | +479% | Bullish | |
| $19.38 | $43.08 | $93.85 | +961% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.71 | $4.06 | $4.86 | +0.00% |
| August 2026 | $3.45 | $4.13 | $5.11 | +1.69% |
| September 2026 | $3.73 | $4.51 | $5.67 | +9.15% |
| October 2026 | $3.83 | $4.67 | $5.95 | +3.53% |
| November 2026 | $3.72 | $4.57 | $5.89 | -1.96% |
| December 2026 | $3.80 | $4.71 | $6.13 | +2.87% |
Click any year to see its month-by-month CCCC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, CCCC is projected to trade between $1.71 and $6.13, averaging $4.06 — a potential gain of 0% from today's $4.06. A consolidation phase looks the most probable path here.
C4 Therapeutics, Inc.'s 2027 outlook centres on $5.82, within a $4.42 to $8.20 range. That is up +43% on the projected 2026 average. That marks a +43% change versus current levels. Momentum favours further upside here.
By 2028, CCCC could reach as high as $11.03, with a base case around $7.43 and support toward $5.41 — roughly +83% from $4.06. Buyers look set to stay in control over this stretch.
Expect CCCC to range from $6.01 to $13.21 through 2029. The $8.55 average target implies a +111% move from current prices. That is up +15% on the projected 2028 average. Momentum favours further upside here.
The CCCC price prediction for 2030 points to an average of $8.71 (low $5.92, high $13.90) — a potential gain of +115% on today's $4.06. Buyers look set to stay in control over this stretch.
In 2031, CCCC is projected to trade between $5.85 and $14.58, averaging $8.88 — a potential gain of +119% from today's $4.06. That is up +2% on the projected 2030 average. Momentum favours further upside here.
C4 Therapeutics, Inc.'s 2032 outlook centres on $9.24, within a $5.92 to $15.56 range. That is up +4% on the projected 2031 average. That marks a +128% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, CCCC could reach as high as $20.83, with a base case around $12.09 and support toward $7.54 — roughly +198% from $4.06. Momentum favours further upside here.
Expect CCCC to range from $9.20 to $26.62 through 2034. The $15.13 average target implies a +273% move from current prices. That is up +25% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The CCCC price prediction for 2035 points to an average of $15.22 (low $9.02, high $27.30) — a potential gain of +275% on today's $4.06. Momentum favours further upside here.
In 2040, CCCC is projected to trade between $12.40 and $45.72, averaging $23.53 — a potential gain of +479% from today's $4.06. That is up +55% on the projected 2035 average. Buyers look set to stay in control over this stretch.
C4 Therapeutics, Inc.'s 2050 outlook centres on $43.08, within a $19.38 to $93.85 range. That is up +83% on the projected 2040 average. That marks a +961% change versus current levels. Momentum favours further upside here.
Investing $1,000 in CCCC today (≈ 246.305419 CCCC) could be worth
$10,610.1
+$9,610.1 (+961%) by 2050 · US Dollar
Based on the average projected CCCC price of $43.08 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CCCCwould be worth at today's price.
$1,000 invested in CCCC on Jul 10, 2025 (≈ 502.51256 CCCC) would be worth
$2,040.2
+$1,040.2 (+104.0%) today · 2.04× · US Dollar
Based on a CCCC entry price of $1.99 vs. today's $4.06.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.3 | $944.19 | -5.6% |
| 1 month ago | $3.87 | $1,049.1 | +4.9% |
| 3 months ago | $2.54 | $1,601.58 | +60.2% |
| 6 months ago | $2.13 | $1,906.1 | +90.6% |
| 1 year ago | $1.99 | $2,040.2 | +104.0% |
| All time (5.0y) ago | $37.8 | $107.41 | -89.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CCCC forecast.
Our base-case forecast reaches $8.10 around 2029.
Implied market cap at $8.10: $895.59M
The multi-year forecast depicts a rising path with year-by-year upside. For 2026 the average price is $4.34 with a min of $1.71 and a max of $7.25, and a neutral sentiment. Moving forward, 2027 shows an average of $7.38 with a 70.1% ROI.
2028 projects an average of $9.56 with a 120.3% ROI, and 2029 an average of $11.67 with a 169% ROI. By 2030, the average is $11.97 with a 175.8% ROI, and 2031–2032 push higher to $12.74 (193.6% ROI) and $14.89 (243.1% ROI) respectively. The trajectory continues to 2033–2035 with averages of $20.69, $25.70, and $26.25 and ROI of 376.8%, 492.2%, and 504.8% respectively.
By 2040 the forecast average rises to $47.16 with a 986.6% ROI, and by 2050 it is $91.79 with a 2015% ROI. These figures reflect bullish sentiment across the long horizon while recognizing the inherent uncertainty in forward-price estimates.
Tap a question to reveal the answer.
The forecast shows an average price of $11.97 in 2030, with a min of $7.95 and a max of $19.50 and a projected ROI of 175.8%; sentiment is bullish.
The outlook becomes bullish from 2027 onward with rising averages and positive ROI (e.g., 2027 ROI 70.1% and 2028 ROI 120.3%). Near-term 2026 is neutral with an average of $4.34 and ROI of 0%.
Yes, in the forecast the 2040 average hits $47.16 and the 2050 average is $91.79, with the 2040 max projected at $94.47 and the 2050 max at $207.09, indicating potential to exceed $50 over the longer term.
Current price is $4.34 and market cap is $479.86M.
The 30-day picture is bullish with RSI 60, SMA50 at $3.60, SMA200 at $2.72, support at $3.11, and resistance at $4.67; the 30-day range is $3.26 to $5.78 and the stock exhibits about 80% annualized volatility.
C4 Therapeutics, Inc. Community Discussion
0Share your C4 Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.